Cargando…

Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan

Objective  To evaluate the clinicopathological features and survival outcomes of mucinous ovarian cancer (MOC) patients in an Asian population. Study Design  Descriptive observational study. Place and Duration of Study  Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan, from January 2001 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamdani, Syed Abdul Mannan, Azhar, Musa, Wahab, Abdul, Yasmeen, Tahira, Siddiqui, Neelam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970748/
https://www.ncbi.nlm.nih.gov/pubmed/36860587
http://dx.doi.org/10.1055/s-0042-1755582
_version_ 1784897964746997760
author Hamdani, Syed Abdul Mannan
Azhar, Musa
Wahab, Abdul
Yasmeen, Tahira
Siddiqui, Neelam
author_facet Hamdani, Syed Abdul Mannan
Azhar, Musa
Wahab, Abdul
Yasmeen, Tahira
Siddiqui, Neelam
author_sort Hamdani, Syed Abdul Mannan
collection PubMed
description Objective  To evaluate the clinicopathological features and survival outcomes of mucinous ovarian cancer (MOC) patients in an Asian population. Study Design  Descriptive observational study. Place and Duration of Study  Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan, from January 2001 to December 2016. Methods  Data of MOC were evaluated for demographics, tumor stage, clinical characteristics, tumor markers, treatment modalities, and outcomes from electronic Hospital Information System. Results  Nine-hundred patients with primary ovarian cancer were reviewed, out of which 94 patients (10.4%) had MOC. The median age was 36 ± 12.4 years. The most common presentation was abdominal distension 51 (54.3%), while the rest presented with abdominal pain and irregular menstruation. Using FIGO (The International Federation of Gynecology and Obstetrics) staging, 72 (76.6%) had stage I, 3 (3.2%) stage II, stage III in 12 (12.8%), and 7 (7.4%) had stage IV disease. The majority of patients 75 (79.8%) had early-stage (stage I/II), while 19 (20.2%) presented with advanced-stage (III & IV). The median follow-up duration was 52 months (range 1–199 months). Among patients with early-stage (I&II), 3- and 5-year progression-free survival (PFS) was 95%, while for advanced stage (III&IV), PFS was 16% and 8%, respectively. The overall survival (OS) in early-stage I&II was 97%, while for advanced stages III & IV, the OS was 26%. Conclusion  MOC is a challenging and rare subtype of ovarian cancer requiring special attention and recognition. Most patients treated at our center presented with early stages and had excellent outcomes, while advanced-stage disease had dismal results.
format Online
Article
Text
id pubmed-9970748
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-99707482023-02-28 Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan Hamdani, Syed Abdul Mannan Azhar, Musa Wahab, Abdul Yasmeen, Tahira Siddiqui, Neelam South Asian J Cancer Objective  To evaluate the clinicopathological features and survival outcomes of mucinous ovarian cancer (MOC) patients in an Asian population. Study Design  Descriptive observational study. Place and Duration of Study  Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan, from January 2001 to December 2016. Methods  Data of MOC were evaluated for demographics, tumor stage, clinical characteristics, tumor markers, treatment modalities, and outcomes from electronic Hospital Information System. Results  Nine-hundred patients with primary ovarian cancer were reviewed, out of which 94 patients (10.4%) had MOC. The median age was 36 ± 12.4 years. The most common presentation was abdominal distension 51 (54.3%), while the rest presented with abdominal pain and irregular menstruation. Using FIGO (The International Federation of Gynecology and Obstetrics) staging, 72 (76.6%) had stage I, 3 (3.2%) stage II, stage III in 12 (12.8%), and 7 (7.4%) had stage IV disease. The majority of patients 75 (79.8%) had early-stage (stage I/II), while 19 (20.2%) presented with advanced-stage (III & IV). The median follow-up duration was 52 months (range 1–199 months). Among patients with early-stage (I&II), 3- and 5-year progression-free survival (PFS) was 95%, while for advanced stage (III&IV), PFS was 16% and 8%, respectively. The overall survival (OS) in early-stage I&II was 97%, while for advanced stages III & IV, the OS was 26%. Conclusion  MOC is a challenging and rare subtype of ovarian cancer requiring special attention and recognition. Most patients treated at our center presented with early stages and had excellent outcomes, while advanced-stage disease had dismal results. Thieme Medical and Scientific Publishers Pvt. Ltd. 2022-08-22 /pmc/articles/PMC9970748/ /pubmed/36860587 http://dx.doi.org/10.1055/s-0042-1755582 Text en MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Hamdani, Syed Abdul Mannan
Azhar, Musa
Wahab, Abdul
Yasmeen, Tahira
Siddiqui, Neelam
Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan
title Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan
title_full Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan
title_fullStr Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan
title_full_unstemmed Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan
title_short Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan
title_sort evaluation of outcomes of mucinous ovarian cancer treated at a tertiary care cancer hospital in pakistan
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970748/
https://www.ncbi.nlm.nih.gov/pubmed/36860587
http://dx.doi.org/10.1055/s-0042-1755582
work_keys_str_mv AT hamdanisyedabdulmannan evaluationofoutcomesofmucinousovariancancertreatedatatertiarycarecancerhospitalinpakistan
AT azharmusa evaluationofoutcomesofmucinousovariancancertreatedatatertiarycarecancerhospitalinpakistan
AT wahababdul evaluationofoutcomesofmucinousovariancancertreatedatatertiarycarecancerhospitalinpakistan
AT yasmeentahira evaluationofoutcomesofmucinousovariancancertreatedatatertiarycarecancerhospitalinpakistan
AT siddiquineelam evaluationofoutcomesofmucinousovariancancertreatedatatertiarycarecancerhospitalinpakistan